{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:38:08Z","timestamp":1773301088113,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["#2010.078"],"award-info":[{"award-number":["#2010.078"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["#110909"],"award-info":[{"award-number":["#110909"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["#110125"],"award-info":[{"award-number":["#110125"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["#KR2291\/4-1\/5-1"],"award-info":[{"award-number":["#KR2291\/4-1\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NMFZ Mainz\/intramural"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00432-016-2229-x","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T13:46:15Z","timestamp":1472564775000},"page":"2263-2273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells"],"prefix":"10.1007","volume":"142","author":[{"given":"Nisintha","family":"Mahendrarajah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"key":"2229_CR1","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/phar.1671","volume":"35","author":"S Afifi","year":"2015","unstructured":"Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O (2015) Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: a focus on vorinostat and panobinostat. Pharmacotherapy 35:1173\u20131188. doi: 10.1002\/phar.1671","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"2229_CR2","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1089\/dna.2011.1575","volume":"31","author":"M Ahmad","year":"2012","unstructured":"Ahmad M et al (2012) Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. DNA Cell Biol 31(Suppl 1):S62\u2013S71. doi: 10.1089\/dna.2011.1575","journal-title":"DNA Cell Biol"},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","volume":"46","author":"F Boschelli","year":"2010","unstructured":"Boschelli F, Arndt K, Gambacorti-Passerini C (2010) Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer 46:1781\u20131789. doi: 10.1016\/j.ejca.2010.02.032","journal-title":"Eur J Cancer"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"12617","DOI":"10.1073\/pnas.1006774107","volume":"107","author":"JE Bradner","year":"2010","unstructured":"Bradner JE et al (2010) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 107:12617\u201312622. doi: 10.1073\/pnas.1006774107","journal-title":"Proc Natl Acad Sci USA"},{"key":"2229_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/leu.2010.114","volume":"24","author":"M Buchwald","year":"2010","unstructured":"Buchwald M, Pietschmann K, M\u00fcller JP, B\u00f6hmer FD, Heinzel T, Kr\u00e4mer OH (2010) Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia 24:1412\u20131421. doi: 10.1038\/leu.2010.114","journal-title":"Leukemia"},{"key":"2229_CR6","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1038\/onc.2012.515","volume":"32","author":"M Buchwald","year":"2013","unstructured":"Buchwald M, Pietschmann K, Brand P, Gunther A, Mahajan NP, Heinzel T, Kr\u00e4mer OH (2013) SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation. Oncogene 32:4913\u20134920. doi: 10.1038\/onc.2012.515","journal-title":"Oncogene"},{"key":"2229_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00432-013-1465-6","volume":"139","author":"D Chan","year":"2013","unstructured":"Chan D et al (2013) Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol 139:1507\u20131514. doi: 10.1007\/s00432-013-1465-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/bjc.2011.42","volume":"104","author":"V Cheriyath","year":"2011","unstructured":"Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC (2011) Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer 104:957\u2013967. doi: 10.1038\/bjc.2011.42","journal-title":"Br J Cancer"},{"key":"2229_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/cpb.47.1","volume":"47","author":"EJ Corey","year":"1999","unstructured":"Corey EJ, Li WD (1999) Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull 47:1\u201310","journal-title":"Chem Pharm Bull"},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jhep.2010.07.021","volume":"54","author":"Y Fujimoto","year":"2011","unstructured":"Fujimoto Y et al (2011) A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J Hepatol 54:629\u2013639. doi: 10.1016\/j.jhep.2010.07.021","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"2229_CR11","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1007\/s00277-004-0850-2","volume":"83","author":"M G\u00f6ttlicher","year":"2004","unstructured":"G\u00f6ttlicher M (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83(Suppl 1):S91\u2013S92. doi: 10.1007\/s00277-004-0850-2","journal-title":"Ann Hematol"},{"key":"2229_CR12","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978","journal-title":"EMBO J"},{"key":"2229_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ejca.2009.01.003","volume":"45","author":"JS Graham","year":"2009","unstructured":"Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45:1129\u20131136. doi: 10.1016\/j.ejca.2009.01.003","journal-title":"Eur J Cancer"},{"key":"2229_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/bjc.2014.589","volume":"112","author":"D Hennig","year":"2015","unstructured":"Hennig D et al (2015) Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells. Br J Cancer 112:329\u2013337. doi: 10.1038\/bjc.2014.589","journal-title":"Br J Cancer"},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"e0126270","DOI":"10.1371\/journal.pone.0126270","volume":"10","author":"M Karaca","year":"2015","unstructured":"Karaca M, Liu Y, Zhang Z, De Silva D, Parker JS, Earp HS, Whang YE (2015) Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding. PLoS ONE 10:e0126270. doi: 10.1371\/journal.pone.0126270","journal-title":"PLoS ONE"},{"key":"2229_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cytogfr.2015.04.002","volume":"26","author":"SK Knauer","year":"2015","unstructured":"Knauer SK, Mahendrarajah N, Roos WP, Kr\u00e4mer OH (2015) The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers. Cytokine Growth Factor Rev 26:405\u2013413. doi: 10.1016\/j.cytogfr.2015.04.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/leu.2012.284","volume":"27","author":"OH Kr\u00e4mer","year":"2013","unstructured":"Kr\u00e4mer OH, Stauber RH, Bug G, Hartkamp J, Knauer SK (2013) SIAH proteins: critical roles in leukemogenesis. Leukemia 27:792\u2013802. doi: 10.1038\/leu.2012.284","journal-title":"Leukemia"},{"key":"2229_CR18","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.18632\/oncotarget.1911","volume":"5","author":"V Licht","year":"2014","unstructured":"Licht V et al (2014) Caspase-3 and caspase-6 cleave STAT1 in leukemic cells. Oncotarget 5:2305\u20132317","journal-title":"Oncotarget"},{"key":"2229_CR19","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1038\/onc.2010.103","volume":"29","author":"Y Liu","year":"2010","unstructured":"Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE (2010) Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 29:3208\u20133216. doi: 10.1038\/onc.2010.103","journal-title":"Oncogene"},{"key":"2229_CR20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1568026615666150813145629","volume":"16","author":"N Ma","year":"2016","unstructured":"Ma N, Luo Y, Wang Y, Liao C, Ye WC, Jiang S (2016) Selective histone deacetylase inhibitors with anticancer activity. Curr Top Med Chem 16:415\u2013426","journal-title":"Curr Top Med Chem"},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1517\/14656566.2015.1031107","volume":"16","author":"ML Mace","year":"2015","unstructured":"Mace ML, Dahl J, Jabbour EJ (2015) Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert Opin Pharmacother 16:999\u20131007. doi: 10.1517\/14656566.2015.1031107","journal-title":"Expert Opin Pharmacother"},{"key":"2229_CR22","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1038\/onc.2014.350","volume":"34","author":"K Mahajan","year":"2015","unstructured":"Mahajan K, Mahajan NP (2015) ACK1\/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. Oncogene 34:4162\u20134167. doi: 10.1038\/onc.2014.350","journal-title":"Oncogene"},{"key":"2229_CR23","doi-asserted-by":"publisher","first-page":"22112","DOI":"10.1074\/jbc.M112.357384","volume":"287","author":"K Mahajan","year":"2012","unstructured":"Mahajan K et al (2012) Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem 287:22112\u201322122. doi: 10.1074\/jbc.M112.357384","journal-title":"J Biol Chem"},{"key":"2229_CR24","doi-asserted-by":"publisher","first-page":"28179","DOI":"10.1074\/jbc.M114.584425","volume":"289","author":"K Mahajan","year":"2014","unstructured":"Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP (2014) ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem 289:28179\u201328191. doi: 10.1074\/jbc.M114.584425","journal-title":"J Biol Chem"},{"key":"2229_CR25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"Maxson JE et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781\u20131790. doi: 10.1056\/NEJMoa1214514","journal-title":"N Engl J Med"},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/0008-5472.CAN-15-0817","volume":"76","author":"JE Maxson","year":"2016","unstructured":"Maxson JE et al (2016) Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis. Cancer Res 76:127\u2013138. doi: 10.1158\/0008-5472.CAN-15-0817","journal-title":"Cancer Res"},{"key":"2229_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10495-014-0967-2","volume":"19","author":"S Mukhopadhyay","year":"2014","unstructured":"Mukhopadhyay S, Panda PK, Sinha N, Das DN, Bhutia SK (2014) Autophagy and apoptosis: Where do they meet? Apoptosis Int J Program Cell Death 19:555\u2013566. doi: 10.1007\/s10495-014-0967-2","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"2229_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/156800910791054149","volume":"10","author":"S M\u00fcller","year":"2010","unstructured":"M\u00fcller S, Kr\u00e4mer OH (2010) Inhibitors of HDACs\u2014Effective drugs against cancer? Curr Cancer Drug Targets 10:210\u2013228","journal-title":"Curr Cancer Drug Targets"},{"key":"2229_CR29","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-13-0626","volume":"12","author":"A Newbold","year":"2013","unstructured":"Newbold A et al (2013) Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther 12:2709\u20132721. doi: 10.1158\/1535-7163.MCT-13-0626","journal-title":"Mol Cancer Ther"},{"key":"2229_CR30","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1182\/blood-2014-12-615906","volume":"125","author":"A Nonami","year":"2015","unstructured":"Nonami A et al (2015) Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood 125:3133\u20133143. doi: 10.1182\/blood-2014-12-615906","journal-title":"Blood"},{"issue":"4","key":"2229_CR101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7164\/antibiotics.30.275","volume":"30","author":"S Omura","year":"1977","unstructured":"Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, Takahashi Y, Masuma R (1977) A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot (Tokyo) 30(4):275\u2013282","journal-title":"J Antibiot (Tokyo)"},{"key":"2229_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.cdd.4401247","volume":"10","author":"J Rozman-Pungercar","year":"2003","unstructured":"Rozman-Pungercar J et al (2003) Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ 10:881\u2013888. doi: 10.1038\/sj.cdd.4401247","journal-title":"Cell Death Differ"},{"key":"2229_CR32","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor Perspect Biol 6:a018713. doi: 10.1101\/cshperspect.a018713","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"2229_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423","author":"NP Shah","year":"2016","unstructured":"Shah NP et al (2016) Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. doi: 10.1002\/ajh.24423","journal-title":"Am J Hematol"},{"key":"2229_CR34","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-06-2569","volume":"13","author":"J Starkova","year":"2007","unstructured":"Starkova J et al (2007) The identification of (ETV6)\/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6\/RUNX1-positive lymphoid leukemic cells. Clin Cancer Res Off J Am Assoc Cancer Res 13:1726\u20131735. doi: 10.1158\/1078-0432.CCR-06-2569","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2229_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.18632\/oncotarget.430","volume":"3","author":"RH Stauber","year":"2012","unstructured":"Stauber RH et al (2012) A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 3:31\u201343","journal-title":"Oncotarget"},{"key":"2229_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.reprotox.2013.07.019","volume":"42","author":"S Stempin","year":"2013","unstructured":"Stempin S, Andres S, Scheer MB, Rode A, Nau H, Seidel A, Lampen A (2013) Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner. Reprod Toxicol 42:49\u201357. doi: 10.1016\/j.reprotox.2013.07.019","journal-title":"Reprod Toxicol"},{"key":"2229_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/CBM-2010-0150","volume":"7","author":"K Trtkova","year":"2010","unstructured":"Trtkova K, Paskova L, Matijescukova N, Kolar Z (2010) Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor. Cancer Biomark Sect A Dis Markers 7:79\u201390. doi: 10.3233\/CBM-2010-0150","journal-title":"Cancer Biomark Sect A Dis Markers"},{"key":"2229_CR38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7888","author":"H Wang","year":"2016","unstructured":"Wang H et al (2016) Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3. Oncotarget. doi: 10.18632\/oncotarget.7888","journal-title":"Oncotarget"},{"key":"2229_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cytogfr.2012.06.005","volume":"23","author":"M Wieczorek","year":"2012","unstructured":"Wieczorek M, Ginter T, Brand P, Heinzel T, Kr\u00e4mer OH (2012) Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev 23:293\u2013305. doi: 10.1016\/j.cytogfr.2012.06.005","journal-title":"Cytokine Growth Factor Rev"},{"key":"2229_CR40","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736\u2013746. doi: 10.1038\/nrc3818","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2229-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2229-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2229-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T22:36:35Z","timestamp":1568327795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2229-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2229-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]}}}